Pear Therapeutics (NASDAQ:PEAR – Get Rating) had its target price trimmed by Citigroup from $13.00 to $12.00 in a research report sent to investors on Tuesday morning, The Fly reports. The firm currently has a buy rating on the stock. Several other analysts have also issued reports on the stock. Chardan Capital reiterated a buy […]